N/A N=251 COVID-19 Vaccine Uptake Trial
Vaccination Refusal · COVID-19
Primary: Vaccine Uptake — 1; 3; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=24 A Study to Learn About the Study Medicine (PF-07293893) at Different Dose Levels in Healthy Adults
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
N/A N=33 Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)
Mild Cognitive Impairment
Primary: Change in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog) — 2.83 score on a scale — p=0.002
N/A N=534 Charge: A Text Messaging-based Weight Loss Intervention
Weight Loss · Obesity
Primary: Average Weight Change — 0.1; -0.4; -3.4; -0.8 Weight in kg
Phase 2 N=637 Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
SARS-CoV Infection · Covid19
Primary: Number of Participants With Solicited Local and Systemic Adverse Events (AE's) — 71; 32; 32; 28 participants
Phase 2 N=35 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Glioblastoma Multiforme
Primary: Maximum Tolerated Dose (MTD) of DSF (Dose-escalation Phase Only) — 375 mg
Phase 2 N=65 Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder
Major Depressive Disorder · Alcohol Use Disorder
Primary: Number of Participants With 50% or Greater Improvement in MADRS Scores From Baseline — 15; 9; 13 Participants
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale
Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
Palmoplantar Pustulosis
Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…
N/A N=20 Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility
Obesity · Dysmobility
Primary: Change in 6 Minute Walk Distance — 1137; 1195 feet — p=0.03
N/A N=64,666 IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
Atrial Fibrillation · Stroke
Primary: Proportion of Patients With Evidence of at Least One OAC Dispensing (Prescription Fill) (Defined as One OAC Dispensing or 4 INR (International Normalized Ratio) Tests)…
Phase 3 N=670 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia · Bacterial Pneumonia
Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants
N/A N=60 DDEP for Lifestyle Modification in Chronic Kidney Disease
Chronic Kidney Diseases
Primary: Change From Baseline in eGFR at 3 Months (Patient-specific) — -1.71; -4.12 ml/min/1.73m^2
N/A N=34 Effect of Dynamic Taping on Landing Biomechanics in Athletes With Symptoms of Patellar Tendinopathy
Biomechanical Phenomena
Primary: Hip Flexion Angles — 86.59; 73.65 degrees — p=0.047
Phase 2 N=348 Effect of Tafoxiparin on Cervical Ripening and Induction of Labor in Term Pregnant Women With an Unripe Cervix
Labor Onset and Length Abnormalities
Primary: Cervical Ripening Rate, Measured by Bishop Score - Slope — 0.86; 0.81; 0.78; 0.62 Slope (Bishop Score/day)